MannKind Corp., a biopharmaceutical firm, on Thursday said it may periodically sell up to $350 million in debt securities, common stock and warrants.

It plans to use the proceeds for clinical trials, research and development, expanding manufacturing operations and general corporate purposes, according to a shelf registration statement filed with the U.S. Securities and Exchange Commission.

Under a shelf registration, a company may sell securities in one or more separate offerings with the size, price and terms to be determined at the time of sale.